Marshall Wace
AVBP icon

Marshall Wace’s ArriVent BioPharma AVBP Stock Holding History

Marshall Wace’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,165
Closed -$811K – 3832
2026
Q1 		$811K Sell
35,165
-63,819
-64% -$1.44M ﹤0.01% 2227
2025
Q4 		$1.99M Sell
98,984
-81,239
-45% -$1.69M ﹤0.01% 1589
2025
Q3 		$3.33M Buy
+180,223
New +$3.54M ﹤0.01% 1372
2025
Q2 		– Sell
-35,851
Closed -$663K – 3265
2025
Q1 		$663K Buy
+35,851
New +$877K ﹤0.01% 1950
2024
Q4 		– Sell
-85,250
Closed -$2M – 3073
2024
Q3 		$2M Buy
+85,250
New +$1.94M ﹤0.01% 1366

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's AVBP Position: Q2 2026 in Review

Marshall Wace sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 35,165 shares — an estimated $811K sold.

Marshall Wace first reported a position in AVBP in Q3 2024 and held it in 5 quarters. The position peaked at $3.33M in Q3 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Marshall Wace reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 35,165 ArriVent BioPharma shares in Q2 2026, an estimated $811K.
  • Marshall Wace first reported a position in ArriVent BioPharma in Q3 2024 and held it in 5 quarters.
  • Marshall Wace's ArriVent BioPharma position peaked at $3.33M in Q3 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.